A Specific Peptide Vaccine Against IDH1(R132H) Glioma.
作者信息
Huang Yuqian, Wang Yongjie, Huang Zhihui
机构信息
College of Pharmacy; Department of Neurosurgery, The Affiliated Hospital, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines; Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.
出版信息
Neurosci Bull. 2022 Feb;38(2):223-225. doi: 10.1007/s12264-021-00791-9. Epub 2021 Nov 5.
Abstract
摘要
相似文献
1
A Specific Peptide Vaccine Against IDH1(R132H) Glioma.一种针对异柠檬酸脱氢酶1（R132H）突变型胶质瘤的特异性肽疫苗。
Neurosci Bull. 2022 Feb;38(2):223-225. doi: 10.1007/s12264-021-00791-9. Epub 2021 Nov 5.
2
Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma.未见血管中心性胶质瘤中异柠檬酸脱氢酶 1 R132H 突变。
Ann Diagn Pathol. 2012 Aug;16(4):255-9. doi: 10.1016/j.anndiagpath.2011.11.003. Epub 2012 Mar 23.
3
Isocitrate dehydrogenase 1 mutation subtypes at site 132 and their translational potential in glioma.异柠檬酸脱氢酶1第132位位点的突变亚型及其在胶质瘤中的翻译潜力。
CNS Oncol. 2018 Jan;7(1):41-50. doi: 10.2217/cns-2017-0019. Epub 2018 Jan 5.
4
Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults.IDH1-R132H 突变缺失预示着老年患者非增强弥漫性胶质瘤的快速进展。
Ann Diagn Pathol. 2012 Jun;16(3):161-70. doi: 10.1016/j.anndiagpath.2011.08.010. Epub 2011 Dec 24.
5
R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.异柠檬酸脱氢酶1（IDH1）基因中的R132H突变通过下调Wnt/β-连环蛋白信号传导来降低人胶质瘤的增殖、细胞存活和侵袭能力。
Int J Biochem Cell Biol. 2016 Apr;73:72-81. doi: 10.1016/j.biocel.2016.02.007. Epub 2016 Feb 6.
6
Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.IDH1 中除非 p.R132H 突变的分离存在于不同的胶质瘤分子亚型中。
Hum Mutat. 2010 Mar;31(3):E1186-99. doi: 10.1002/humu.21201.
7
IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.异柠檬酸脱氢酶1（IDH1）R132H突变通过Nrf2途径调节胶质瘤的化疗敏感性。
Oncotarget. 2017 Apr 25;8(17):28865-28879. doi: 10.18632/oncotarget.15868.
8
Characterizing invading glioma cells based on IDH1-R132H and Ki-67 immunofluorescence.基于异柠檬酸脱氢酶1（IDH1）-R132H和Ki-67免疫荧光对侵袭性胶质瘤细胞进行特征分析。
Brain Tumor Pathol. 2014 Oct;31(4):242-6. doi: 10.1007/s10014-013-0172-y. Epub 2014 Jan 3.
9
Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.免疫组织化学和基因测序检测弥漫性胶质瘤活检标本中 IDH1-R132H 突变的价值和局限性。
J Neuropathol Exp Neurol. 2011 Aug;70(8):715-23. doi: 10.1097/NEN.0b013e31822713f0.
10
IDH1 mutation diminishes aggressive phenotype in glioma stem cells.异柠檬酸脱氢酶 1 突变减弱了神经胶质瘤干细胞中的侵袭表型。
Int J Oncol. 2018 Jan;52(1):270-278. doi: 10.3892/ijo.2017.4186. Epub 2017 Nov 3.
引用本文的文献
1
Unraveling the immunosuppressive microenvironment of glioblastoma and advancements in treatment.解析胶质母细胞瘤的免疫抑制微环境及治疗进展。
Front Immunol. 2025 May 15;16:1590781. doi: 10.3389/fimmu.2025.1590781. eCollection 2025.
2
Dysregulation of Iron Homeostasis Mediated by FTH Increases Ferroptosis Sensitivity in TP53-Mutant Glioblastoma.由FTH介导的铁稳态失调增加了TP53突变型胶质母细胞瘤对铁死亡的敏感性。
Neurosci Bull. 2025 Apr;41(4):569-582. doi: 10.1007/s12264-024-01322-y. Epub 2024 Dec 12.
3
Clinical immunotherapy in glioma: current concepts, challenges, and future perspectives.胶质瘤的临床免疫治疗：当前概念、挑战与未来展望。
Front Immunol. 2024 Nov 1;15:1476436. doi: 10.3389/fimmu.2024.1476436. eCollection 2024.
4
Multidisciplinary Management of Isocitrate Dehydrogenase-Mutated Gliomas in a Contemporary Molecularly Defined Era.在当今分子定义时代对异柠檬酸脱氢酶突变型神经胶质瘤进行多学科管理。
J Clin Oncol. 2024 Jul 20;42(21):2588-2598. doi: 10.1200/JCO.23.02195. Epub 2024 Jun 4.
5
Efficacy and Safety of Vaccines After Conventional Treatments for Survival of Gliomas: A Systematic Review and Meta-Analysis.胶质瘤常规治疗后疫苗用于生存的疗效和安全性：一项系统评价和荟萃分析
Oncol Rev. 2024 Apr 19;18:1374513. doi: 10.3389/or.2024.1374513. eCollection 2024.
6
The Oncogenesis of Glial Cells in Diffuse Gliomas and Clinical Opportunities.胶质细胞在弥漫性神经胶质瘤中的致癌作用及临床机遇。
Neurosci Bull. 2023 Mar;39(3):393-408. doi: 10.1007/s12264-022-00953-3. Epub 2022 Oct 13.
本文引用的文献
1
A vaccine targeting mutant IDH1 in newly diagnosed glioma.针对新诊断的神经胶质瘤中突变 IDH1 的疫苗。
Nature. 2021 Apr;592(7854):463-468. doi: 10.1038/s41586-021-03363-z. Epub 2021 Mar 24.
2
Management of glioblastoma: State of the art and future directions.脑胶质瘤的治疗：现状与未来方向。
CA Cancer J Clin. 2020 Jul;70(4):299-312. doi: 10.3322/caac.21613. Epub 2020 Jun 1.
3
Brain immunology and immunotherapy in brain tumours.脑肿瘤的脑免疫学和免疫疗法。
Nat Rev Cancer. 2020 Jan;20(1):12-25. doi: 10.1038/s41568-019-0224-7. Epub 2019 Dec 5.
4
Homeobox B8 Targets Sterile Alpha Motif Domain-Containing Protein 9 and Drives Glioma Progression.同源盒 B8 靶向无活性丝氨酸/苏氨酸激酶结构域蛋白 9 并驱动神经胶质瘤进展。
Neurosci Bull. 2020 Apr;36(4):359-371. doi: 10.1007/s12264-019-00436-y. Epub 2019 Oct 23.
5
Neoantigen vaccine: an emerging tumor immunotherapy.肿瘤新生抗原疫苗：一种新兴的肿瘤免疫疗法。
Mol Cancer. 2019 Aug 23;18(1):128. doi: 10.1186/s12943-019-1055-6.
6
Glioma.胶质瘤。
Nat Rev Dis Primers. 2015 Jul 16;1:15017. doi: 10.1038/nrdp.2015.17.
7
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.2016 年世界卫生组织中枢神经系统肿瘤分类：概述。
Acta Neuropathol. 2016 Jun;131(6):803-20. doi: 10.1007/s00401-016-1545-1. Epub 2016 May 9.
8
IDH mutations in cancer and progress toward development of targeted therapeutics.癌症中的异柠檬酸脱氢酶（IDH）突变与靶向治疗药物研发进展
Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013.
9
Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.基于肿瘤中1p/19q、异柠檬酸脱氢酶（IDH）和端粒酶逆转录酶（TERT）启动子突变的胶质瘤分组
N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.
10
A vaccine targeting mutant IDH1 induces antitumour immunity.针对突变 IDH1 的疫苗可诱导抗肿瘤免疫。
Nature. 2014 Aug 21;512(7514):324-7. doi: 10.1038/nature13387. Epub 2014 Jun 25.
Zotero 插件